Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. Februar 2026 22:56 ET | Quelle: InnoCare Pharma

InnoCare Announces Key Developments of Critical Clinical Studies

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.
12. Februar 2026 21:21 ET | Quelle: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

The current indications of soficitinib under development are strategically positioned within the vast dermatology market.
29. Januar 2026 03:17 ET | Quelle: InnoCare Pharma

Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.
27. November 2025 20:55 ET | Quelle: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.